Ikushima et al. showed that Oct4 and Sox2 are critical in retaining tumorigenicity, and that knock-down of Oct4 increased the sensitivity of glioma cells to temozolomide [43]. This evidence concerns the gene POU5F1 and central nervous system cancer.